Full text here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369496/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369496/ From the discussion section: > In

Full text here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369496/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369496/ From the discussion section: > In this study, we have shown differences in the specificity of polyclonal serum antibodies acquired by infection versus vaccination with mRNA-1273. The neutralizing activity of vaccine sera is more targeted to the RBD than for convalescent sera, with the majority of vaccine sera losing all detectable neutralization at a 1:25 cutoff after depletion of RBD-directed antibodies. (emphasis mine) From the conclusion: > Despite these limitations, our results in conjunction with other recent studies (19) suggest that mRNA vaccines and infection elicit somewhat distinct anti-spike antibody responses. Therefore, it is important to differentiate antibody immunity acquired by different means when assessing the impact of viral evolution. Considerable effort is being expended to identify emerging antigenic variants of SARS-CoV-2 and determine which ones might evade immunity (3, 7, 8, 35). Our findings suggest that the results could vary depending on the source of immunity. Furthermore, carefully characterizing and comparing the specificity of antibody immunity elicited by additional vaccine modalities could provide a basis for determining whether some vaccine responses will be more resistant to viral evolution.